{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,8]],"date-time":"2025-12-08T22:00:50Z","timestamp":1765231250717},"reference-count":9,"publisher":"Institute of Physiology of the Czech Academy of Sciences","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Physiol Res"],"abstract":"<jats:p>Glucagon-like-peptide 2 (GLP-2) is an endogenous enteroendocrine physiological trophic peptide. Glepaglutide is a novel long-acting GLP-2 analog under development for the treatment of patients with Short Bowel Syndrome (SBS). The objective of this work was to compare the small intestinal trophic effects in both genders following short (1 week) versus long-term (26-39 weeks) GLP-2 treatment in Wistar rats and Beagle dogs. Following both short- and long-term treatment with glepaglutide, a significant dose-dependent intestinotrophic effect was seen in both genders and species. At all doses increased length and weight of the small intestine as well as macroscopic thickening and villous hypertrophy were noted in all segments of the small intestine, without any differences between genders. The findings were still present following a 6-week recovery period, indicating long-acting intestinotrophic effects of glepaglutide. These studies demonstrate that a long-acting GLP-2 analogue (glepaglutide) has a fast onset and long duration of intestinotrophic action with similar profile in both genders and species (rat and dog).<\/jats:p>","DOI":"10.33549\/physiolres.934839","type":"journal-article","created":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T13:15:24Z","timestamp":1652966124000},"page":"323-326","source":"Crossref","is-referenced-by-count":5,"title":["Short- versus Long-Term, Gender and Species Differences in the Intestinotrophic Effects of Long-Acting Glucagon-Like Peptide 2 Analog"],"prefix":"10.33549","author":[{"given":"P","family":"Glerup","sequence":"first","affiliation":[{"name":"Research and Development, Zealand Pharma, S\u00f8borg, Denmark. PGlerup@zealandpharma.com"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K","family":"Sonne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Berner-Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J","family":"Skarbaliene","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"19169","published-online":{"date-parts":[[2022,4,30]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Benjamin MA, McKay DM, Yang PC, Cameron H, Perdue MH. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut. 2000;47(1):112-119. https:\/\/doi.org\/10.1136\/gut.47.1.112","DOI":"10.1136\/gut.47.1.112"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Drucker DJ, Yusta B. Physiology and pharmacology of the entero- endocrine hormone glucagon-like peptide-2. Annu Rev Physiol. 2014; 76:561-583. https:\/\/doi.org\/10.1146\/annurev-physiol-021113-170317","DOI":"10.1146\/annurev-physiol-021113-170317"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Hartmann B, Harr MB, Jeppesen PB, Wojdemann M, Deacon CF, Mortensen PB, Holst JJ. In vivo and in vitro degradation of glucagon-like peptide-2 in humans. J Clin Endocrinol Metab 2000;85:2884-2888. https:\/\/doi.org\/10.1210\/jcem.85.8.6717","DOI":"10.1210\/jcem.85.8.6717"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"ICH M3 (R2) Non-clinical safety studies for the conduct of human clinical trials for pharmaceuticals.","DOI":"10.1007\/978-1-4614-5950-7_14"},{"key":"ref4","unstructured":"NPS Pharmaceuticals (2012). GATTEX (teduglutide [rDNA origin]): Highlights of prescribing information."},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Wallis K., Walters J.R., Forbes A. Review article: glucagon-like peptide 2--current applications and future directions. Aliment Pharmacol Ther 2007; 25:365-72. https:\/\/doi.org\/10.1111\/j.1365-2036.2006.03193.x","DOI":"10.1111\/j.1365-2036.2006.03193.x"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Warner BW. GLP-2 as therapy for the short-bowel syndrome. Gastroenterology 2001; 120(4): 1041-1043. https:\/\/doi.org\/10.1053\/gast.2001.22560","DOI":"10.1053\/gast.2001.22560"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Sinclair E, Drucker D.J. Proglucagon-derived peptides: mechanisms of action and therapeutic potential. Physiology 2005, 20: 357-365. https:\/\/doi.org\/10.1152\/physiol.00030.2005","DOI":"10.1152\/physiol.00030.2005"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Tavares W., Drucker D.J., Brubaker P.L. Enzymatic- and renal-dependent catabolism of the intestinotropic hormone glucagon-like peptide-2 in rats. Am J Physiol Endocrinol Metab 2000; 278:E134-E139. https:\/\/doi.org\/10.1152\/ajpendo.2000.278.1.E134","DOI":"10.1152\/ajpendo.2000.278.1.e134"}],"container-title":["Physiological Research"],"original-title":[],"language":"en","deposited":{"date-parts":[[2022,5,19]],"date-time":"2022-05-19T13:15:28Z","timestamp":1652966128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.biomed.cas.cz\/physiolres\/pdf\/2022\/71_323.pdf"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,30]]},"references-count":9,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,4,30]]}},"URL":"https:\/\/doi.org\/10.33549\/physiolres.934839","relation":{},"ISSN":["1802-9973","0862-8408"],"issn-type":[{"value":"1802-9973","type":"electronic"},{"value":"0862-8408","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4,30]]}}}